The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Goutam Chakraborty(National Centre for Cell Science), Philip W. Kantoff(Dana-Farber Brigham Cancer Center), Nagavarakishore Pillarsetty(Memorial Sloan Kettering Cancer Center), Michael J. Morris(The University of Texas Southwestern Medical Center), Bastien Nguyen(Eli Lilly (United States)), Tiffany A. Traina, Pedram Razavi(Memorial Sloan Kettering Cancer Center), Stephen B. Solomon(Memorial Sloan Kettering Cancer Center), Nikolaus Schultz(Memorial Sloan Kettering Cancer Center), Jeremy C. Durack(Memorial Sloan Kettering Cancer Center), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Andreas G. Wibmer(Memorial Sloan Kettering Cancer Center), Romina Ghale(Memorial Sloan Kettering Cancer Center), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Lorelei A. Mucci(Harvard University), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Wassim Abida(Memorial Sloan Kettering Cancer Center), Howard I. Scher(Kantonsspital Baselland Standort Bruderholz), Christoph Kreitzer(Memorial Sloan Kettering Cancer Center), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Rahim Hirani(New York Medical College), Sai Harisha Rajanala(Memorial Sloan Kettering Cancer Center), Matthew G. Vander Heiden(Massachusetts Institute of Technology)
Cited by 51
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k